belagenpumatucel-l
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2003 (NCT01058785)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108577 ↗
Also known as
- belagenpumatucel l
- belagenpumatucel-l
- belagenpumatucel-l
- lucanix
- lucanix
- lucanix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01279798 | N/A | Oct 29, 2010 | Activate Immunotherapy |
| NCT00676507 | Phase 3 | Jul 1, 2008 | Activate Immunotherapy |
| NCT01058785 | Phase 2 | Mar 1, 2003 | Activate Immunotherapy |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Activate Immunotherapy | For profit | 3 | 3 | 3 | 2003 |
1 organizations
Page 1 / 1